Evaluation of posterior capsule opacification of the Clareon IOL vs the Acrysof IOL using a human capsular bag model

Session Details

Session Title: Posterior Capsule Opacification/IOL Power Calculations

Session Date/Time: Tuesday 17/09/2019 | 14:00-16:00

Paper Time: 14:44

Venue: Free Paper Forum: Podium 2

First Author: : A.Hillenmayer GERMANY

Co Author(s): :    C. Wertheimer   S. Kassumeh   A. von Studnitz   A. Ohlmann   S. Priglinger   W. Mayer              

Abstract Details

Purpose:

Posterior capsule opacification (PCO) after cataract surgery is influenced by intraocular lens (IOL) design and material. The following is an ex vivo comparison of PCO between the Clareon vs. the AcrySof IOL in human capsular bags.

Setting:

Cell- and molecular biology laboratory, Department of Ophthalmology, LMU Munich, Germany

Methods:

Twenty cadaver capsular bags from 10 human donors were used, with the novel hydrophobic IOL (Clareon, CNA0T0) being implanted in one eye and the other eye of the same donor receiving the AcrySof IOL (SN60WF) following phacoemulsification cataract surgery. Five capsular bags of 3 donors served as controls without IOL. Cellular growth of lens epithelial cells was photo-documented daily. The primary endpoint was the time until full coverage of the posterior capsule by cells. Furthermore, immunofluorescence staining of capsular bags for the fibrotic markers f-actin, fibronectin, alpha smooth muscle actin, and collagen type 1 were performed.

Results:

The new Clareon IOL did not show any disadvantages in terms of days until full cell coverage of the posterior capsule in comparison to the AcrySof (p>0.99). Both, the Clareon (p=0.01, 14.8 days) and the AcrySof IOL (p=0.005, 15.7 days) showed a slower PCO development in comparison to the control (8.6 days). The fibrotic markers f-actin, fibronectin, alpha smooth muscle actin, and collagen type 1 were equally distributed between the two IOLs and differed from the control

Conclusions:

A comparable performance has been found in the ex vivo formation of PCO between the two IOLs. Long-term clinical studies are necessary to reach final conclusions.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives consulting fees, retainer, or contract payments from a competing company